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Abstract
Receptor for advanced glycation end products (RAGE) is a multiligand member of the immunoglobulin superfamily of cell
surface molecules whose repertoire of ligands includes advanced glycation end products (AGEs), amyloid fibrils,
amphoterins and S100/calgranulins. The overlapping distribution of these ligands and cells overexpressing RAGE results in
sustained receptor expression which is magnified via the apparent capacity of ligands to upregulate the receptor. We
hypothesize that RAGE-ligand interaction is a propagation factor in a range of chronic disorders, based on the enhanced
accumulation of the ligands in diseased tissues. For example, increased levels of AGEs in diabetes and renal insufficiency,
amyloid fibrils in Alzheimer’s disease brain, amphoterin in tumors and S100/calgranulins at sites of inflammation have been
identified. The engagement of RAGE by its ligands can be considered the ‘first hit’ in a two-stage model, in which the second
phase of cellular perturbation is mediated by superimposed accumulation of modified lipoproteins (in atherosclerosis),
invading bacterial pathogens, ischemic stress and other factors. Taken together, these ‘two hits’ eventuate in a cellular
response with a propensity towards tissue destruction rather than resolution of the offending pathogenic stimulus.
Experimental data are cited regarding this hypothesis, though further studies will be required, especially with selective low
molecular weight inhibitors of RAGE and RAGE knockout mice, to obtain additional proof in support of our
concept. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
The receptor for advanced glycation end products
(RAGE) is a member of the immunoglobulin super-
family whose expression is upregulated at sites of
diverse pathologies, from atherosclerosis to Alzheim-
er’s disease [1]. One of the salient features of the
receptor is its recognition of families of ligands,
rather than a single polypeptide. A prime example
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is the binding of S100/calgranulins to RAGE [2].
S100A12, also termed extracellular newly identi¢ed
RAGE binding protein (EN-RAGE), was the ¢rst
S100/calgranulin member shown to interact with
RAGE in a dose-dependent and saturable manner
resulting in activation of cellular targets. S100B de-
rived from bovine brain was demonstrated to com-
pete with S100A12 for binding to RAGE. Similarly,
RAGE has been shown to interact with L-sheet
¢brils composed of di¡erent subunits/monomers,
amyloid A, amyloid-L peptide, prion peptide, or
amylin [3,4]. In each case, the most probable conclu-
sion is that RAGE interacts with conformational de-
terminants in the ligands allowing recognition of
polypeptides with varied primary sequences. This in-
dicates the importance of understanding the structure
of ligand recognition sites in RAGE. X-Crystallog-
raphy studies are in progress to accomplish this ob-
jective.
Several other features of RAGE biology are im-
portant to mention at the outset. First, there is an
unusual sustained juxtaposition of ligand and recep-
tor in tissues. At sites of accumulated advanced glyc-
ation end products (AGEs) in the vasculature, for
example, there is increased expression of the receptor
in cells of the vessel wall, including endothelium,
vascular smooth muscle cells and invading mononu-
clear phagocytes [5]. Similarly, in amyloid-rich tis-
sues, upregulation of RAGE is observed in parenchy-
mal cells, such as neurons, as well as mononuclear
phagocyte elements, including microglia in Alzheim-
er’s disease brain [3]. Based on the apparently acti-
vated state of cells expressing RAGE at such loci (as
re£ected by sustained activation of NF-UB, expres-
sion of cytokines and cell adherence molecules, etc.),
we speculate that the overlapping distribution of re-
ceptor and ligand results in prolonged receptor acti-
vation. Our studies have demonstrated that one facet
of RAGE-mediated cellular stimulation includes in-
creased expression of the receptor itself. Thus, one
can envision a positive feedback loop in which li-
gand-receptor interaction increases expression of
the receptor, thereby augmenting subsequent
RAGE-induced cellular activation. This situation
contrasts with other receptors, such as the LDL re-
ceptor, in which increased levels of ligand decrease
expression of the receptor [6]. In fact, the only means
we know to strongly downregulate RAGE is to in-
terrupt the cycle of ligand engagement of the recep-
tor with soluble RAGE (see below) or blocking anti-
bodies.
These considerations suggest that RAGE could
function as a propagation factor in a number of dis-
orders according to a two-hit model. The ¢rst hit is
comprised of RAGE engagement by its ligands. Li-
gands such as AGEs and amyloid-L peptide (AL) are
present for long times in tissues (endogenous clear-
ance mechanisms apparently do not function e⁄-
ciently), and have the capacity to bring about sus-
tained ligand-receptor interaction. The result of
ligand engagement appears to be cellular activation,
rather than clearance. In this context, RAGE-medi-
ated endocytosis followed by lysosomal degradation
is a slow process [7]. By contrast, the type A macro-
phage scavenger receptor is much more e⁄cient
when these two have been compared with respect
to clearance of AL [7]. The principal outcome of
RAGE-ligand interaction is a change in the cellular
set point resulting in a new basal state of activation.
In the vasculature, this has been shown to include
expression of vascular cell adhesion molecule-1
(VCAM-1) and induction of vascular hyperperme-
ability (i.e., increased vascular leakage) [8,9]. With
a superimposed stimulus, such as accumulation of
modi¢ed lipoproteins, cellular perturbation is further
magni¢ed. Rather than returning to homeostasis, cel-
lular signal transduction mechanisms favor aug-
mented dysfunction resulting in acceleration of athe-
rogenesis (see below). The same logic can be applied
to in£ammatory/infectious stimuli, in which RAGE-
induced activation of e¡ector cells prevents their nor-
mal participation in protective and reparative pro-
cesses.
In this brief review, the functional consequences of
RAGE interaction with its di¡erent ligands will be
summarized. These observations provide a context
for considering the biology of this receptor in a spec-
trum of physiologically and pathophysiologically rel-
evant situations.
2. AGEs and RAGE
Mechanisms of chronic vascular dysfunction have
been much less studied than the acute response to
proin£ammatory cytokines. The transient induction
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of leukocyte adherence molecules (especially in post-
capillary venules), tissue factor (in certain vascular
beds) and vascular hyperpermeability following ex-
posure of endothelium to agents such as tumor ne-
crosis factor-K and Interleukin 1L are hallmarks of
the acute in£ammatory response [10]. However, the
situation is less de¢ned in chronic vascular diseases
such as diabetes. The inexorable accumulation of
AGEs in the vessel wall provides a means of distin-
guishing normal from diabetic vessels [11^13]; i.e.,
the diabetic vessel has a memory based on its pro-
longed exposure to high glucose because of AGE
modi¢cation of basement membrane-associated mac-
romolecules. Such a site for deposition of AGEs al-
lows their interaction with critical cells of the vessel
wall, including endothelium and smooth muscle. The
presence of AGEs in the vasculature has also been
shown to promote trapping of macromolecules per-
colating through the vessel wall [11], and would be
expected to a¡ect cellular tra⁄cking as well (for ex-
ample, by engaging cells bearing RAGE on their
surfaces). Furthermore, AGE cross-links change elas-
ticity of the vessel wall [11]. Because of the close
association of AGEs with cellular elements, it was
logical to assess the molecular basis of AGE-cellular
interactions. These considerations led us to isolate
cell-associated polypeptides capable of mediating
the interaction with AGEs. Since our initial goal
was to focus on the vasculature, lung, with its rich
blood vessel network, provided an ideal starting
point.
Our studies led to the isolation of a new member
of the immunoglobulin superfamily which we named
RAGE [14,15]. The extracellular domain includes
three immunoglobulin-like regions; an N-terminal
V-type domain followed by two C-type domains
(termed C and CP). The principal ligand binding por-
tion is the V-domain [16]. Though the C- and CP-
domains may not directly bind ligands, they could
have important roles in stabilizing the V-domain
for mediating its interaction(s) with ligands. RAGE
has a single transmembrane spanning domain and a
43 amino acid cytosolic tail which is highly charged.
This cytosolic tail lacks known signaling motifs
(phosphorylation sites, kinase domains, etc.), but is
critical for RAGE-dependent cellular activation. A
truncated form of RAGE from which the cytosolic
tail has been deleted binds ligands identically to wild-
type RAGE, though it does not mediate induction of
cellular activation [2]. Cells expressing the latter var-
iant of RAGE (termed tail-deletion, dominant-nega-
tive or DN-RAGE), even in the presence of wild-type
RAGE, display inhibition of RAGE-induced signal-
ing. This probably re£ects a requirement for cluster-
ing of RAGE cytosolic tails, following engagement
by the ligands, into a particular orientation which
facilitates binding of cytosolic signaling complexes.
The nature of the signaling molecules which bind
Fig. 1. Interaction of RAGE and CML-bovine serum albumin. Dose dependence: CML-modi¢ed bovine serum albumin (310 mmol
CML per mol lysine) was immobilized in microtiter wells and a radioligand binding assay was performed with the indicated amount
of 125I-sRAGE alone or in the presence of a 50-fold molar excess of unlabeled sRAGE. Speci¢city: the experiment was performed as
in ‘Dose dependence’, except that 125I-sRAGE was added at 100 nM, and the indicated antibody was added (70 Wg/ml in each case).
In each case, speci¢c binding, de¢ned as total (binding observed with 125I-sRAGE alone) minus nonspeci¢c (binding observed with
125I-sRAGE in the presence of 50-fold excess unlabeled sRAGE) binding, is shown. Adapted from [16].
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to the RAGE cytosolic tail is currently under inten-
sive study.
The major AGE adduct of macromolecules found
in vivo consists of Ne-(carboxymethyl)lysine (CML)
[17]. We have found that CML-modi¢ed proteins
(albumin, ovalbumin etc.) bind to RAGE [16]. The
interaction of 125I-soluble (s) RAGE with CML-
modi¢ed bovine serum albumin is dose-dependent
and saturable with KdW73 nM (Fig. 1). Note that
the interaction of 125I-sRAGE with CML albumin
was blocked by antibodies to RAGE or CML, as
well as by excess unlabeled sRAGE (Fig. 1). There
was no e¡ect of preimmune IgG. Furthermore, CML
alone was not a competitor, indicating that CML
must be presented to the receptor in the appropriate
context of a protein/peptide in order for receptor
recognition to occur. Competitive binding experi-
ments with puri¢ed RAGE domains showed that
only excess unlabeled V-domain inhibited binding
of 125I-sRAGE to CML-albumin, not the C- or CP-
domains [16]. Such CML adducts have the capacity
to activate cells bearing RAGE resulting in nuclear
translocation of NF-UB, induction of VCAM-1 ex-
pression and induction of chemotaxis. Consistent
with this premise, following intravenous infusion of
CML-bovine serum albumin into mice, expression of
VCAM-1 was observed in extracts of lung by immu-
noblotting. VCAM-1 induction in this setting was
blocked by anti-RAGE IgG or sRAGE (see below)
indicating its dependence on RAGE-induced cellular
activation. Preparations of AGE-modi¢ed polypep-
tides made in vitro often display about 30% modi¢-
cation of lysine residues which is a considerably
greater degree of modi¢cation than occurs in vivo.
The latter has been estimated to be in the range of
1.7^4.95 mmol of CML per mol of lysine based on
studies of lens proteins and skin collagen obtained
from elderly humans [18]. Thus, our studies of CML-
induced RAGE activation have included prepara-
tions with as low as 0.8 mmol CML per mole of
lysine [16]. Even with such preparations, RAGE-in-
duced cellular activation was observed with CML-
ovalbumin, but not with the native protein.
These data indicate that CML adducts of proteins
are ligands for RAGE. The presence of low levels of
CML in tissues provides a situation in which the
basal state of activation of cells in the vasculature
could be subtly changed over time. Since CML ac-
cumulation is accelerated by superimposed renal in-
su⁄ciency and oxidant stress, especially that associ-
ated with in£ammation, it is possible that properties
of host e¡ector cells are signi¢cantly altered in the
AGE-rich environment via their interaction with
RAGE.
These results led us to study the possible contribu-
tions of AGE-RAGE interaction in more complex
biologic systems. In cell culture, experiments with
AGEs, either those prepared in vitro or those derived
from patients with diabetes or renal failure, demon-
strated that consequences of AGE-cellular interac-
tions appeared to result from engagement of
RAGE. For example, AGE-L2-microglobulin iso-
lated from the urine of patients with dialysis-related
amyloidosis (DRA) induced chemotaxis and activa-
tion of mononuclear phagocytes [19]. Each of these
e¡ects was prevented by blockade of RAGE. Patients
with DRA develop arthritis closely associated with
deposition of AGE-L2-microglobulin in the joint
space [20]. Macrophage activation is a prominent
component of the resulting joint in£ammation and
eventual bone destruction. AGE interaction with
RAGE on mononuclear phagocytes would provide
a plausible mechanism for modulating cellular prop-
erties in this setting. Consistent with this hypothesis,
immunohistochemical studies demonstrated the pres-
ence of RAGE-bearing cells in joints of patients with
DRA which colocalized with the monocyte marker
CD68 and displayed an overlapping distribution with
AGE epitopes [19].
Red blood cells from patients with diabetes were
found to bear cell surface AGEs capable of binding
RAGE expressed by cultured endothelial cells [9,21].
The interaction of diabetic red cells with endothelium
resulted in increased di¡usional transit of tracers
across the endothelial monolayer [9]. This change
in properties of the endothelium was dependent on
RAGE, as it was blocked by anti-RAGE IgG. At
this point in our studies, it was clearly essential to
move to in vivo model systems in order to determine
if RAGE was a central receptor for AGE-induced
cellular perturbation. For these studies it would be
necessary to block RAGE for longer times, at least
several months, and polyclonal anti-RAGE immuno-
globulins would not be suitable reagents. As an alter-
native strategy, we prepared truncated form of
RAGE, sRAGE, comprised of only the extracellular,
BBAMCR 14671 27-11-00
A.M. Schmidt et al. / Biochimica et Biophysica Acta 1498 (2000) 99^111102
ligand binding domain [9]. In the presence of excess
sRAGE, ligands bind to the soluble receptor and
cellular activation is abrogated since the cell surface
receptor remains unoccupied by ligands. Experiments
in animal species and humans studied to date display
low (picomolar) levels of sRAGE in the plasma, pro-
duced either by proteolytic processing or actual ex-
pression of truncated forms of the receptor. Thus,
exogenous sRAGE of the same species evades im-
mune surveillance mechanisms. Consistent with this
observation, soluble RAGE has been administered to
animals for over 6 months with no evidence of a
local or systemic immune response.
Because of our results with diabetic red cells and
the permeability of endothelial monolayers in vitro,
our ¢rst in vivo studies assessed the AGE-RAGE
axis in terms of its e¡ect on vascular hyperperme-
ability in diabetic rats. Vascular hyperpermeability
is a subtle and early hallmark of diabetic complica-
tions. Increased leakage of albumin in the urine at
early stages in diabetes (microalbuminuria) is consid-
ered an important harbinger of later vascular com-
plications [11]. Rats treated with streptozotocin be-
came diabetic and were observed for 9^11 weeks
(Fig. 2). Increased leakage of radiolabeled albumin
was determined by the tissue-blood isotope ratio
(TBIR; a ratio of 125I-albumin deposited to red cell
pooling in the indicated tissue, the latter based on
accumulation of 51Cr-labeled erythrocytes) [9,22].
Using this assay, increased vascular leakage of albu-
min was present in a range of tissues from the dia-
betic animals, compared with untreated controls. An-
imals receiving a single treatment with sRAGE
displayed marked suppression of vascular hyperper-
meability. This indicated that vascular dysfunction,
as manifested by increased leakiness of the blood
vessels, was reversible at this stage of diabetes, and
that RAGE-dependent mechanisms were likely in-
volved.
Diabetic macrovascular disease is a major cause of
morbidity and mortality, and is not equally respon-
sive to rigorous glucose control compared with mi-
crovascular disease. These considerations led us to
assess the e¡ect of RAGE blockade in a murine
model of accelerated atherosclerosis-diabetes [23].
ApoE null mice rendered diabetic with streptozoto-
cin develop atherosclerosis at an accelerated rate
compared with euglycemic controls; lesions develop
more rapidly, are greater in number, cover a greater
area of the vessel surface and display increased com-
plexity (presence of cholesterol clefts, necrosis and/or
¢brous caps) compared with the same time point in
nondiabetic apoE null mice. Using this model, mice
were treated with either sRAGE or vehicle (mouse
Fig. 2. Administration of sRAGE decreases vascular hyperpermeability in diabetic rats. Diabetic rats (induced with streptozotocin and
observed for 9^11 weeks) were infused with sRAGE at the indicated dose (intraperitoneally) and then tissue-blood isotope ratio was
determined to assess vascular permeability. Adapted from [9].
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serum albumin), and lesion formation was assessed
6 weeks later. The sRAGE-treated apoE null diabetic
mice showed strong inhibition of lesion formation;
there were fewer lesions which occupied less area in
the sRAGE-treated group compared with those ani-
mals receiving vehicle alone. The lesions which were
present in sRAGE-treated diabetic apoE null mice
appeared to be arrested at an earlier stage; i.e.,
they were predominately fatty streaks compared
with a much larger percentage of complex lesions
in vehicle-treated apoE null diabetic mice. These re-
sults have been extended to LDL receptor null and
transgenic apoB mice, and to the db/db strain (the
latter providing a genetic model of insulin resistance,
thus obviating the need for streptozotocin) with sim-
ilar results.
We have hypothesized that sRAGE inhibition of
lesion formation in atherosclerosis-prone diabetic
mice is due to interception of RAGE-ligand interac-
tions. There is no change in the level of glycemia or
hemoglobin A1c in mice treated with sRAGE [23].
Furthermore, total cholesterol, which rises on induc-
tion of diabetes, and lipoprotein pro¢le, remain un-
a¡ected by administration of sRAGE. However, an-
imals treated with sRAGE displayed strikingly
decreased AGE content in the vasculature and tis-
sues. Furthermore, complexes of sRAGE bound to
AGE-immunoreactive species could be detected in
the plasma of treated animals, consistent with their
interaction in vivo. In terms of mechanisms through
which sRAGE prevents AGE accumulation in tis-
sues, both increased clearance (possibly re£ected by
the presence of sRAGE-AGE complex in the plasma)
and decreased formation (the latter may be due to
suppression of oxidant stress, a part of the RAGE-
induced signaling cascade) are possible. These data
highlight a lipid- and glycemia-independent means
through which atherogenesis is accelerated in dia-
betic animals. According to these models, the activa-
tion of RAGE appears to have a central role in
accelerating atherosclerosis and leading to the forma-
tion of complex lesions with in¢ltrating mononuclear
phagocytes and smooth muscle cells.
Our subsequent studies have addressed the issue as
to whether RAGE blockade might impact on other
complications in diabetes. Many of these studies are
underway, but early results in nephropathy and pe-
riodontal disease have suggested a striking bene¢cial
e¡ect of blocking RAGE. One important considera-
tion in these studies is the possibility that more than
one RAGE ligand may be present in tissues at the
same time. This is discussed further below, and in-
dicates the potential for several ligands to reinforce
RAGE-dependent cellular activation.
3. Amyloid ¢brils and RAGE
Another family of disorders whose manifestations
include chronic vasculopathy include the amyloido-
ses. Cerebral vascular amyloid angiopathy, in which
amyloid deposits in the basement membrane of cer-
ebral blood vessels, is often associated with Alzheim-
er’s disease [24]. Patients with the Dutch-type variant
of AL have the most striking evidence of vascular
amyloid accumulation; in fact, the mutant amyloid
preferentially deposits in the vessels, to a much great-
er degree than that in cerebral parenchyma, and re-
sults in hemorrhagic strokes [25]. In view of the
many e¡ects of AL on cellular elements of the vessel
wall, as well as in the cerebral parenchyma itself, we
began an intensive search to identify cellular interac-
tion sites for AL. To our surprise, once again we
identi¢ed RAGE as a cell surface receptor capable
of mediating AL-induced cellular perturbation [3]. It
is important to note that RAGE binds AL in the
nanomolar range (50^150 nM), and that at these
levels, we have found RAGE-bearing cells to display
increased susceptibility to the e¡ects of AL. The type
of AL-RAGE-mediated changes in cellular properties
that we have observed include expression of macro-
phage-colony stimulating factor (M-CSF) [26], acti-
vation of NF-UB [3], activation of caspase 3, and
induction of DNA fragmentation. Whereas neurons
undergo RAGE-dependent apoptosis after prolonged
incubation with AL fragments, microglia demon-
strate sustained cellular activation; the latter includes
expression of cytokines and M-CSF, and chemotaxis.
Each of these e¡ects is blocked by anti-RAGE IgG
or in the presence of excess sRAGE, indicating the
key role of RAGE. However, it is important to note
that the outcome of RAGE ligation on these two cell
types is di¡erent. The reasons for these di¡erences
are not yet clear, but probably relate to the special-
ized properties of neurons versus microglia. For ex-
ample, although neurons elaborate M-CSF in re-
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sponse to incubation with AL, they are unable to
respond this mediator, since they do not express
the receptor, c-fms [26]. In contrast, microglia ex-
press c-fms and, thus, can respond to M-CSF present
in Alzheimer’s disease brain. M-CSF promotes cell
survival, and even proliferation, in the presence of
AL, and may prove to be a key nutritive factor for
microglia in the harsh AL-rich environment. We pro-
pose a scheme in which neuronal-derived M-CSF
draws microglia to sites of AL deposition at early
stages in Alzheimer’s disease. Microglia £ourish in
this milieu, and products of their activation further
damage neurons. The increased levels of M-CSF in
Alzheimer’s disease brain and cerebrospinal £uid are
consistent with this hypothesis [26], though further
experiments will be required to fully verify our con-
cept. An important consideration in these studies is
to compare receptor-dependent and receptor-inde-
pendent events related to the interaction of AL
with cells. At high concentrations of AL (10^50
WM), receptor-dependent events are overwhelmed
by receptor-independent phenomena, such as AL-in-
duced formation of oxygen free radicals and direct
AL destabilization of membranes [27^29]. Thus, at
these concentrations, blocking RAGE has no e¡ect
on the toxic e¡ects of AL on cells. However, at nano-
molar levels of AL, receptor-dependent phenomena
predominate (i.e., blocking RAGE prevents cellular
e¡ects of AL). The clear question concerns which of
these situations is relevant in vivo. One possible sce-
nario is that lower concentrations of AL earlier in
Alzheimer’s disease render receptor-dependent mech-
anisms of cellular perturbation more relevant at these
times. In contrast, later in the course of Alzheimer’s
disease, when levels of AL are much higher, nonspe-
ci¢c (receptor-independent) cytotoxicity might be-
come the predominant mode of cellular perturbation.
Studies are in progress in transgenic models to di-
rectly test the possible role of RAGE in cellular per-
turbation underlying Alzheimer-type pathology.
In order to more directly test the consequences of
RAGE serving as a receptor for amyloid, we also
performed experiments with ¢brils comprised of
amylin, amyloid A, and prion-derived peptide [30].
These experiments showed that only the ¢brillar
form of these peptides bound to RAGE (binding of
immobilized ¢brils to the receptor was dose-depen-
dent and displayed KdW50^150 nM, as with the
AGE ligands and AL described above). When pre-
sented to the receptor in random conformation, none
of these peptides bound RAGE. Similarly, RAGE
did not bind collagen or elastin ¢brils. Furthermore,
erabutoxin B, a protein with high L-sheet content,
but which does not form ¢brils, did not bind to
RAGE. These data suggested that RAGE could
serve as a cell surface receptor for L-sheet ¢brils. In
vitro studies demonstrated RAGE-dependent cellular
activation in cultured BV-2 microglial cells exposed
Fig. 3. In a model of systemic amyloidosis, administration of sRAGE suppresses splenic NF-UB activation and accumulation of amy-
loid A. Animals were treated with amyloid enhancing factor/silver nitrate either alone, or with daily administration (intraperitoneally)
with the indicated concentration of sRAGE. Animals were sacri¢ced by humane euthanasia and splenic tissue was obtained to prepare
nuclear extracts for NF-UB or for assessment of amyloid A ¢bril burden (the number above the bar showing amyloid A burden indi-
cates the P value. The electrophoretic mobility shift assay was performed with a consensus 32P-labeled NF-UB probe. ‘Cold’ indicates
a lane in which excess unlabeled NF-UB probe was added. Nuclear extracts from HeLa cells were added as a positive control.
Adapted from [30].
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to each of these amyloid ¢brils. Because of the avail-
ability of models of systemic amyloidosis [31,32], as
well as the accessibility of the amyloid-cellular inter-
action to inhibition by sRAGE or anti-RAGE
F(abP)2 (i.e., amyloid deposition occurs in areas ac-
cessible to the systemic circulation, rather than be-
hind the blood-brain barrier as it does in models of
Alzheimer-type pathology), we were able to carefully
examine the role of RAGE in cellular perturbation
and amyloid deposition [30]. Treatment of mice with
amyloid enhancing factor/silver nitrate was used to
induce deposition of amyloid A in the spleen. Accu-
mulation of splenic amyloid was closely correlated
with expression of cell stress markers, such as heme
oxygenase type 1, Interleukin 6, and M-CSF, as well
as activation of NF-UB (Fig. 3, NF-UB). Analysis of
RAGE expression demonstrated that levels of the
receptor increased in the spleen, and its distribution
parallelled that for deposition of the amyloid. These
data strongly suggested the possibility that RAGE-
amyloid A might interact in vivo. Thus, we per-
formed experiments in the presence of sRAGE or
anti-RAGE F(abP)2 to determine if blocking access
of ligands to the receptor might a¡ect cellular per-
turbation or amyloid deposition, focusing on the
spleen. Animals receiving sRAGE or anti-RAGE
F(abP)2 displayed comparable elevation of plasma
serum amyloid A, compared with those treated
with vehicle. However, RAGE blockade suppressed
evidence of cellular perturbation based on inhibition
of heme oxygenase type I, M-CSF and Interleukin 6
expression and NF-UB activation (Fig. 3, NF-UB).
Furthermore, amyloid deposition in the spleen was
also suppressed by RAGE blockade (Fig. 3, amyloid
A ¢bril burden). These experiments also provided
direct evidence of amyloid A-RAGE interaction; im-
munoprecipitation of plasma from mice treated with
sRAGE demonstrated complexes of amyloid A and
sRAGE.
These studies demonstrate that RAGE binds amy-
loid ¢brils and mediates cellular responses in the
nanomolar range. Studies in genetically manipulated
mice will be necessary to directly prove the role of
RAGE, especially experiments with RAGE null mice
and animals overexpressing wild-type receptor. These
mice can then be crossed with models of amyloid
pathology, such as mice overexpressing transgenes
including mutant forms of amyloid precursor protein
associated with deposition of AL in the brain. Such
studies are an important focus of our current work
on RAGE.
4. S100/calgranulins and RAGE
The interaction of RAGE with AGEs and amyloid
¢brils seemed most likely to be fortuitous. Neither of
these structures is present under physiologic condi-
tions, and, thus, we sought a ligand for the receptor
in normal tissues. Northern analysis of RAGE in
normal human tissues displayed highest levels of
RAGE transcripts in the lung (Fig. 4) [15,33]. Fur-
ther studies showed lung to contain the greatest
amount of RAGE antigen, leading us to begin the
search for natural ligands of RAGE in this tissue.
The extracellular domain of RAGE was immobilized
on a⁄nity columns, and protein extracts of lung
based on their ability to bind RAGE. Two polypep-
tides were isolated using this puri¢cation and assay
system [34]. The ¢rst was a member of the ampho-
terin family (see below) and the second was a mem-
ber of the S100/calgranulin family, EN-RAGE or
S100A12. As mentioned above, RAGE not only
bound S100A12/EN-RAGE, but also interacted
Fig. 4. Northern analysis of RAGE and L-actin transcripts in
normal human tissues. Adapted from [33].
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with S100B [2]. This has led us to suggest that
RAGE may engage a spectrum of S100/calgranulins
with the interaction mediated by common structural
determinants in the ligands.
Incubation of S100A12/EN-RAGE with trans-
formed murine macrophages (BV-2 cells) resulted in
elaboration of Interleukin 1L and tumor necrosis fac-
tor-K (Fig. 5) [2]. In each case, transfection of the
cells to express dominant-negative (DN; also termed
tail-deleted receptor)-RAGE prevented expression of
the cytokines, even in the presence of wild-type
RAGE on the BV-2 cells (Fig. 5). Thus, DN-
RAGE does function as a dominant negative for
blocking the e¡ects of RAGE-dependent cellular ac-
tivation. This experiment, along with studies with
anti-RAGE IgG/F(abP)2 and sRAGE have shown
that RAGE is an important cellular interaction site
for S100/calgranulins. The recognition that a single
receptor might mediate the e¡ect of multiple S100/
calgranulin family members in vivo posed easily test-
able questions: would RAGE mediate the e¡ect of
S100/calgranulins in delayed-type hypersensitivity
and other in£ammatory disorders? Our strategy
was to block RAGE using anti-RAGE F(abP)2 and
sRAGE in animal models of in£ammation.
Our ¢rst experiments employed a murine model of
delayed-type hypersensitivity in which methylated
bovine serum albumin was used as the preparatory
and provocative agent [2]. Severe edema and in£am-
mation was evident in the footpad, along with acti-
vation of the transcription factor NF-UB and expres-
sion of Interleukin 2 and tumor necrosis factor-K
transcripts. Animals treated with anti-RAGE
F(abP)2 or sRAGE showed striking suppression of
the in£ammatory response. Furthermore, blockade
of RAGE also inhibited nuclear translocation of
NF-UB, as well as expression of Interleukin 2 and
tumor necrosis factor-K, indicating that preventing
ligand access to the receptor impacted on the in£am-
matory cascade at a very proximal step. These initial
results were extended to a murine model of colitis in
Interleukin 10 null mice [35]. These mice have been
shown to develop colitis, associated with activation
of NF-UB in colonic tissue and systemic expression
of tumor necrosis factor-K [2]. Administration of
sRAGE had a strong protective e¡ect mitigating
the locally destructive in£ammatory response, as
well as plasma levels of tumor necrosis factor-K.
In the case of the delayed-type hypersensitivity
model, anti-S100A12/EN-RAGE F(abP)2 fragments
were also delivered to the animals [2]. This had an
inhibitory e¡ect, though not as potently as blocking
RAGE. Experiments using anti-S100A12/EN-RAGE
and anti-RAGE F(abP)2 showed a marked suppres-
sion of in£ammation. Since our anti-S100A12/EN-
RAGE antibody is polyclonal and raised to the in-
Fig. 5. Induction of cytokines (IL-1L, and TNF-K antigens) by transformed murine microglial cells (BV-2 cells) exposed to lipopoly-
saccharide (LPS), bovine serum albumin (BSA) or EN-RAGE/S100A12 (at the indicated concentration). BV-2 cells were either mock-
transfected or transfected to overexpress dominant-negative (DN)-RAGE. Adapted from [2].
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tact protein, it is not selective for only this S100/
calgranulin family member. In fact, it is likely to
display immunoreactivity with many family mem-
bers. Thus, we believe that our results support a
role for S100/calgranulins interacting with RAGE
as an important component of an evolving in£am-
matory response. However, it is di⁄cult to rule out
contributions of other RAGE ligands, such as CML
adducts which are also likely to form in the in£am-
matory milieu. The identi¢cation of RAGE as a cell
surface target of S100/calgranulins provides a means
to test the contribution of this interaction in a range
of settings based on blockade of RAGE. This is tech-
nically simpler than blocking or suppressing express-
ing the large S100/calgranulin family.
5. Amphoterins and RAGE
Amphoterins are part of the family of high mobil-
ity group 1 nonhistone chromosomal DNA binding
proteins [36,37]. Although their function in gene reg-
ulation/structure is not known, they have been
shown to exert e¡ects following their release from
cells. In vitro studies have shown that amphoterin
promotes neurite outgrowth and provides a site for
the assembly of enzyme/substrate complexes leading
to the generation of plasmin [36,37]. Amphoterin ex-
pression is also associated with tumors, and recent
studies have shown amphoterin to be a late mediator
of endotoxin toxicity in vivo [38]. Although these
data might appear to comprise an apparently discon-
nected set of observations, it seemed possible that
RAGE, via its interaction with amphoterin, could
provide a basis for drawing together at least some
of these e¡ects.
First, we demonstrated that RAGE bound ampho-
terin selectively and in a saturable manner [34].
Based on these observations, studies were performed
with primary cultures of rat cortical neurons plated
on amphoterin-coated substrates. Neurite outgrowth
was found to depend on RAGE-amphoterin interac-
tion. Subsequently, this observation was extended by
the laboratory of Dr. Heikki Rauvala (University of
Helsinki) by their demonstration that expression of
dominant-negative RAGE blocked the e¡ect of am-
photerin, in terms of induction of neurite outgrowth,
and triggering of a signaling pathway involving Rac
and cdc42 [39]. The presence of RAGE at the leading
edge of neurites, where it could engage amphoterin,
suggested the potential for the receptor to mediate
cell migration. Furthermore, if amphoterin anchored
to cell surface RAGE provided a site for plasmin
generation, this would further favor an invasive cel-
lular phenotype. These considerations led us to ana-
lyze roles for RAGE in the migration and invasion
of tumor cells.
The possible relevance of RAGE to tumor biology
was underscored by immunoblotting studies showing
higher levels of RAGE in many tumors compared
with the normal tissue counterpart (breast, colon,
kidney, stomach, etc.) [40]. For these studies, two
experimental tumor models were employed, local/pri-
mary tumors (rat C6 glioma cells) and metastasis
(Lewis Lung model). In each case, the tumor cells
were found to express both RAGE and amphoterin.
First, primary tumors were raised in immunocom-
promised mice following injection of wild-type C6
glioma cells [40]. Tumor volume was diminished in
the presence of anti-RAGE F(abP)2 or sRAGE, but
there was no e¡ect of nonimmune F(abP)2. To fur-
ther analyze the role of RAGE, stably transfected
lines of C6 glioma cells were made overexpressing
either wild-type RAGE, DN-RAGE, sRAGE or vec-
tor alone [40]. When tumors were raised following
local injection of these clones, there was a dramatic
di¡erence in the volume (Fig. 6) and histologic ap-
pearance of the resulting neoplasms which formed.
Whereas tumors overexpressing wild-type receptor
were very large, compared with vector controls, tu-
mor volume was markedly diminished in tumors
comprised of cells in which RAGE was blocked (tu-
mors comprised of C6 glioma cells overexpressing
DN-RAGE or sRAGE). Pathologic studies showed
that blockade of RAGE correlated with the forma-
tion of small, well-circumscribed tumors during the
experimental period. In contrast, tumors overex-
pressing wild-type RAGE grew rapidly and invaded
the surrounding tissue very e⁄ciently.
These observations were next extended to the
Lewis Lung tumor model of metastasis [40]. Follow-
ing resection of the primary tumor, lung metastases
were compared in mice treated with sRAGE or ve-
hicle alone. There was a striking decrease in the num-
ber of surface lung metastases observed in mice re-
ceiving sRAGE. These data in both primary and
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metastatic tumor models led us to probe mechanisms
underlying the protective e¡ect of sRAGE. C6 glio-
ma cells overexpressing wild-type RAGE plated on
amphoterin-coated matrices displayed strong activa-
tion of mitogen-activated protein kinases, including
p38, SAPK (stress-activated protein kinase) and Erk
(extracellular regulated kinase) 1/2. Downstream ef-
fects of these and other signaling mechanisms trig-
gered by RAGE-ligand interaction led to increased
cell migration and expression of matrix metallopro-
teinases. One likely consequence of these RAGE-
induced changes in cellular properties was the in-
creased invasiveness of C6 glioma cells overexpress-
ing RAGE in assays using Matrigel. These data
are consistent with our in vivo observations that
following implantation of tumor cells, those in
which RAGE was blocked (by overexpression of
DN-RAGE or sRAGE) displayed a delay in cell mi-
gration and proliferation (without an associated
change in the apoptotic index). We propose that
RAGE blockade induces a type of transient dor-
mancy of the tumor cells. In contrast, there did not
appear to be an e¡ect of RAGE expression on tumor
vasculature. These data suggest the possibility that
inhibitors of RAGE might be combined with agents
with anti-angiogenic and direct tumor cell cytotoxic
activity for a maximal e¡ect on tumor properties. In
addition, it is important to mention that in contrast
to murine tumors, in which cell proliferation and
angiogenesis must occur over days for tumor survival
and growth, human tumors have a much more pro-
tracted time course, over years (especially in the ini-
tial phases). Because of this consideration, we are
optimistic that blockade of RAGE may prove to be
an e¡ective adjunct to currently envisioned therapies.
6. Conclusion/hypotheses
The multiligand character of RAGE allows it to
participate in an apparently wide spectrum of patho-
logic events. A common denominator of these path-
Fig. 6. Tumors were raised in immunocompromised mice by injecting either mock-transfected C6 glioma cells or C6 glioma cells sta-
bly transfected to overexpress full-length RAGE, tail-deletion (or dominant-negative) RAGE or sRAGE. Tumors were allowed to
grow, and then animals were sacri¢ced and tumor volume determined. Adapted from [40].
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ologies is the role of RAGE as a propagator of cel-
lular dysfunction. This occurs due to ligand induc-
tion of the receptor, sustained ligand-induced cellular
activation, and the presence of RAGE ligands in the
tissues for long times. Thus, in atherosclerotic vascu-
lature, the presence of both AGEs and S100/calgra-
nulins reinforces RAGE-dependent cellular activa-
tion. In Alzheimer’s disease, the presence of AL
¢brils occurs along with S100 proteins again results
in the presence of two RAGE ligands. In in£amma-
tory settings, S100/calgranulins, AGEs, and, poten-
tially, amphoterin could be present at lesional sites.
RAGE triggers a cascade of signaling mechanisms
whose analysis has just begun. Activation of p21ras
and phosphatidylinositol 3-kinase recruits pathways
involving mitogen-activated protein kinases [41,42].
In addition, Rho family small GTPases are activated,
especially cdc42 and Rac, potentially important in
RAGE-induced changes in cell migration [39]. The
generation of reactive oxygen species, an early event
after ligation of the receptor, may be fundamental
for many RAGE-induced changes in cellular proper-
ties. The important point is that from the myriad of
pathways recruited by RAGE-induced cellular acti-
vation, it is virtually impossible, a priori, to predict
with certainty the outcome of RAGE-dependent ac-
tivation in a particular cell type. Thus, in the case of
mononuclear phagocytes, RAGE-dependent stimula-
tion results in activated phenotype with increased
chemotaxis and release of proin£ammatory cyto-
kines. In contrast, in the case of neurons, RAGE-
induced cellular activation ultimately results in in-
duction of programmed cell death.
Many studies remain to be done concerning the
contribution of RAGE to in£ammatory disorders,
diabetic complications and amyloidoses. The re-
agents for these studies, including means to block
RAGE and genetically manipulated mice (knockouts
and transgenics overexpressing wild-type and domi-
nant negative RAGE), are becoming available. Thus,
an understanding of RAGE in the broader context of
the biology of host response mechanisms should be
possible in the coming years.
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